pancreatic cancer

Polaris Group has started dosing patients in its Phase I trial of ADI-PEG 20 in combination with nab-paclitaxel and gemcitabine to treat advanced pancreatic cancer.

The company claims that ADI-PEG 20 is being developed to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesise arginine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

ADI-PEG 20 is designed to deplete the external supply of arginine which is believed to support the survival and growth of cancer cells.

"We are excited to start this new trial and explore potential benefits of the combination in the clinical setting."

The depletion of external supply of arginine will kill arginine-dependent cancer cells while leaving the patient’s normal cells unharmed.

Polaris Medical Affairs executive vice-president John Bomalaski said: "Combination of ADI-PEG 20 with gemcitabine has been shown to have greater inhibition of pancreatic tumour growth than either treatment alone in a mouse xenograft study.

"We are excited to start this new trial and explore potential benefits of the combination in the clinical setting."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Currently, ADI-PEG 20 is also being evaluated in combination with cisplatin in melanoma and ovarian cancer, as well as in combination with doxorubicin in HER2 negative breast cancer.

In addition, the drug is being tested in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.

Besides the ADI-PEG 20 programme, Polaris is also researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilises a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

Image: Histopathogic image of pancreatic adenocarcinoma arising in the pancreas head region. Photo: courtesy of KGH.